Ketamine Masterclass Part 1: What ketamine actually does to the brain

The Ketamine Masterclass Part 1

Part 1 — What ketamine actually does to the brain, why chronic use can damage the body, and why the same molecule can be both a rapid-acting antidepressant and a drug of dependence.

A pillar guide distinguishing established findings from hypotheses where the science is still unsettled.

What this guide covers

Part 1: The Core Mechanism

Most people first encounter ketamine through the phrase “NMDA receptor antagonist.” That’s true, but on its own it explains very little. Here’s the fuller picture.

The central character: glutamate

The brain’s major excitatory neurotransmitter is glutamate, which signals through several receptor families. Particularly NMDA receptors, AMPA receptors, and kainate receptors. Ketamine primarily interferes with NMDA receptors: it is an open-channel blocker, meaning it enters and blocks the receptor’s ion channel while that channel is active.

The paradox: ketamine blocks an excitatory receptor, yet can produce increased downstream excitatory signaling.

The disinhibition model

One influential model focuses on inhibitory GABA interneurons, which act as a brake in the circuit:

Glutamate neuron → GABA interneuron → glutamate neuron.

Ketamine blocks NMDA receptors on inhibitory interneurons
The interneuron becomes less active
Less GABA is released
The excitatory neuron becomes disinhibited
More glutamate becomes available, stimulating AMPA receptors

So, paradoxically: NMDA blockade → disinhibition → increased glutamate/AMPA signaling. This is a leading explanation for ketamine’s rapid effects, though the precise circuit-level mechanism remains an active research question.

AMPA: an underrated star of the story

A major hypothesis holds that increased AMPA signaling downstream of NMDA blockade is important for the antidepressant effect:

ketamine → NMDA modulation → glutamate changes → AMPA activation → intracellular signaling → increased synaptic plasticity → potentially improved neural circuit function.

The 2024 Neuropsychopharmacology review specifically highlights the convergence of NMDA blockade, glutamate signaling, AMPA receptors, BDNF-TrkB and synaptic plasticity.

BDNF: the next major character

BDNF (brain-derived neurotrophic factor) is involved in neuronal growth, survival, learning and synaptic plasticity. Ketamine appears capable of increasing BDNF-related signaling via a pathway roughly like:

NMDA blockade → changes in eEF2 kinase/eEF2 signaling → increased translation of BDNF → BDNF activates TrkB receptors → synaptic plasticity, often involving mTORC1 signaling that regulates protein synthesis for synaptic remodeling.

This is one reason scientists became so interested in ketamine. It doesn’t merely chang neurotransmitter levels. It appears capable of producing rapid changes in synaptic function.

What “neuroplasticity” actually means

Ketamine clinics often say ketamine “rewires the brain.” That’s an oversimplification.

Neuroplasticity broadly means the nervous system’s ability to change its structure or function in response to activity and experience. Ketamine appears capable of temporarily altering the conditions under which synapses can change. Sometimes described as opening a plasticity window. It does not mean a single dose permanently rewires the brain. The relationship between ketamine-induced plasticity, psychotherapy, behavior and long-term outcomes remains an active research area.

A theory this explains: ketamine-assisted psychotherapy

In severe depression, entrenched patterns of negative self-evaluation, rumination, avoidance, hopelessness, emotional rigidity can become very stable. If ketamine temporarily creates a biological state conducive to plasticity and psychotherapy or behavioral experience around that window supplies new information, the result could be strengthened adaptive circuits. This is why ketamine-assisted psychotherapy is scientifically interesting but it remains a hypothesis-driven treatment model, not proof that every session permanently rewires someone.

Part 2: Dissociation and the K-Hole

What dissociation actually is

Ketamine can profoundly alter how the brain integrates sensory information, body signals, spatial information, self-awareness, memory and environmental awareness. The result is dissociation, a sense of being present but not really in one’s body, or of the world happening while being observed from somewhere else. At stronger exposure this can become extremely intense, which is the basis of the recreational phenomenon known as a K-hole.

Why ketamine is so different from classical psychedelics

LSD and psilocybin primarily involve 5-HT2A serotonin receptor signaling. Ketamine primarily involves NMDA/glutamatergic signaling. All three can dramatically alter consciousness through substantially different pharmacology, which is why ketamine is best classified as a dissociative anesthetic rather than simply another psychedelic.

Part 3: Reward, Tolerance and Dependence

The dopamine / reward system

Ketamine isn’t exclusively a glutamate story. Research also implicates reward circuitry and dopamine in its reinforcing properties. This is particularly relevant to recreational use:

A simple demosstration as below:

ketamine → altered glutamatergic signaling → changes in reward-related circuits → pleasurable/dissociative experience → reinforcement → repeated use → adaptation/tolerance → potential dependence.

Reviews describe interacting glutamate, dopamine, prefrontal/hippocampal and mesolimbic reward pathways in ketamine’s addictive potential.

Why doesn't everyone who uses ketamine become addicted?

Addiction isn’t determined by a drug alone. It’s an interaction between drug, brain, person, environment, frequency, reinforcement and psychological vulnerability. For some people ketamine remains occasional experimentation; for others;

a pleasure → repetition → tolerance → craving → escalating-use pattern develops.

Ketamine use disorder is recognized in the modern literature, though the evidence base for treating it is still underdeveloped compared with alcohol, opioids or stimulants.

Tolerance

Tolerance means the same exposure produces less effect over time. An initially intense experience gradually feels insufficient, which can encourage increasing exposure. The real danger isn’t just wanting a stronger experience. Increasing frequency and cumulative exposure is closely associated with the chronic physical harms that make ketamine particularly unusual, especially urinary-system toxicity.

Part 4: Chronic Physical Toxicity

Brain vs. bladder: acute brain effects can disappear relatively quickly, but chronic physical consequences can persist much longer. Someone can feel completely normal the next morning while repeated exposure is still contributing to cumulative physiological harm. One reason ketamine acquired a reputation as a relatively “clean” recreational drug. Subjective recovery is much faster than tissue recovery.

Ketamine-induced bladder disease

This is one of the strongest chronic-harm signals in the literature. Repeated heavy exposure can produce severe urinary tract disease. In other words;

ketamine/metabolites → urinary excretion → exposure of bladder tissues → inflammation and tissue injury → ulcerative cystitis / reduced bladder capacity → ureteral involvement → potential kidney damage.

The 2026 ACMD regulatory reviews identify urinary tract injury as one of ketamine’s major chronic harms, related to dose and frequency.

Why the bladder is such a characteristic target

Ketamine and its metabolites are substantially eliminated through the urinary system, so the urinary tract repeatedly encounters these compounds.

The exact mechanism of injury isn’t fully settled, but chronic exposure is strongly associated with bladder inflammation, ulceration, fibrosis, reduced bladder capacity, ureteric abnormalities, hydronephrosis and kidney injury.

At the severe end, this becomes a major urological disease, not simply “frequent urination.”

The feedback loop

This is one of the most interesting aspects of ketamine dependence. In simple terms;

Frequent ketamine use → bladder injury → painful urination → psychological distress → ketamine temporarily changes perception of pain/distress → continued use → more bladder injury.

This vicious cycle means the drug can end up maintaining the very physical problem it is temporarily helping the person psychologically escape.

The kidneys

Severe ketamine-induced urinary disease can move beyond the bladder. The ureters can narrow or become damaged, interfering with urine drainage, allowing pressure to build upstream and affecting the kidneys. Severe chronic toxicity is more accurately described as a urinary tract / kidney disease rather than just “K-bladder.”

The liver and bile ducts

A newer, less publicly recognized concern. Recent regulatory assessments specifically flag hepatobiliary toxicity as an emerging ketamine-associated harm, involving the liver, bile ducts and biliary system. Some chronic users have developed abnormalities in bile-duct and liver function.

This evidence is less mature than the evidence for ketamine-induced cystitis, so causality and prevalence should be stated cautiously — but it warrants continued study.

What about permanent brain damage?

This deserves more nuance than it usually gets on social media. Studies report cognitive deficits and brain changes in frequent, heavy ketamine users, with working and episodic memory repeatedly investigated. But there are methodological problems.

Heavy ketamine users often also use alcohol, cannabis, stimulants, MDMA and other drugs, and may differ from controls in sleep, socioeconomic circumstances, psychiatric illness, education and pre-existing vulnerabilities. So an observed brain difference does not equal proven ketamine-caused permanent brain damage which is an important scientific boundary.

Part 5: The Depression Paradox

How can the same drug help and harm?

Chronic heavy recreational exposure can be associated with cognitive and psychiatric problems. Yet carefully controlled ketamine exposure can produce rapid antidepressant effects. Both can be true because pharmacology isn’t simply “drug X = good” or “drug X = bad”.

The biological outcome depends heavily on exposure pattern, dose, frequency, context and individual biology. Medical ketamine shouldn’t be used to justify recreational use, and recreational harms shouldn’t automatically invalidate legitimate medical applications.

Why the antidepressant effect can happen so quickly

Conventional antidepressants largely modify monoamine systems (serotonin, norepinephrine, dopamine) and their therapeutic effects often take weeks to work. Ketamine acts on the glutamate system, whose downstream effects can rapidly modify synaptic signaling and plasticity. In simple terms;

NMDA → glutamate → AMPA → BDNF/TrkB → mTOR/eEF2 and related pathways → synaptic plasticity.

This is one of the central mechanistic models behind rapid antidepressant action.

But scientists still don't fully agree on the mechanism

“NMDA blockade increases BDNF” is a useful model, not the final word.

Active research also examines R-ketamine, esketamine, hydroxynorketamine metabolites, opioid-system involvement, inflammatory pathways, microglia, distinct NMDA receptor populations, AMPA signaling, and network-level brain effects. The literature describes multiple proposed mechanisms rather than one settled pathway.

The holy grail in psychiatry: the effect without the baggage

Imagine a drug offering ketamine’s antidepressant effect without dissociation, intoxication, abuse potential, cognitive impairment or cardiovascular effects. That would be enormously valuable, and it’s essentially a major goal of next-generation glutamatergic antidepressant research. Researchers are investigating whether particular metabolites or other NMDA/glutamate modulators can reproduce therapeutic effects without the full ketamine experience.

R-ketamine

Racemic ketamine contains both R- and S- forms; esketamine is the S-form.

Researchers are investigating whether R-ketamine might have a distinct antidepressant profile from esketamine, including potentially different dissociative effects. But this is an active research question, not an established fact that R-ketamine is the “safe version.”

Paradox #2: could ketamine help treat other addictions?

Researchers are investigating whether ketamine could help treat some substance-use disorders, including alcohol use disorder. Some studies show promising effects, particularly when ketamine is combined with psychotherapy, but systematic reviews emphasize the evidence remains mixed and larger, better-controlled trials are needed.

Hence the paradox, a drug capable of producing dependence may also become a tool for treating dependence on other drugs. This paradox is not unique to ketamine, but it is an especially interesting case.

Where the Science Currently Stands

Three tiers of confidence — from settled fact to open question.

Strong Evidence

Debated Mechanism

Still Developing

A Correction Worth Noting

Ketamine withdrawal has sometimes been described as not physically significant. That should be updated.

Recent literature describes withdrawal and dependence, though the evidence base is still limited and the syndrome isn’t equivalent to dangerous alcohol/benzodiazepine withdrawal. A 2024 systematic review found only 12 studies on pharmacological treatment of ketamine use disorder, covering just 368 participants, with evidence quality rated very low.

The scientifically honest position: ketamine can produce dependence and withdrawal, but the syndrome is far less understood than opioid, alcohol or benzodiazepine dependence.

Coming Next in This Series

Part 1 covered the neuroscience foundation. The series continues with:

Sources

This page is educational and does not provide dosing or use guidance. If you or someone you know is struggling with ketamine or another substance, speak with a doctor or a local drug-treatment service.